Report of Foreign Issuer (6-k)
May 13 2019 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May, 2019
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8
9GS
(Address
of principal executive office)
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must
be typed or printed electronically and provided to
an
ris
.
Date:
13 May
2019
|
Name of
applicant
:
|
GlaxoSmithKline plc
|
|
Name of scheme:
|
GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan
|
|
Period of return:
|
From:
|
1 November 2018
|
To:
|
30 April 2019
|
|
Balance of unallotted securities under scheme(s) from previous
return:
|
547,331
|
|
Plus:
The amount by
which the block scheme(s) has been increased since the date of the
last return (if any increase has been applied
for):
|
0
|
|
Less:
Number
of
securities
issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
393,607
|
|
Equals:
Balance
under scheme(s) not yet issued/allotted at end of
period:
|
153,724
|
|
|
|
Name of contact:
|
Victoria Whyte
|
|
Telephone number of contact:
|
020 8047 5000
|
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must
be typed or printed electronically and provided to
an
ris
.
Date:
13 May
2019
|
Name of
applicant
:
|
GlaxoSmithKline plc
|
|
Name of scheme:
|
GlaxoSmithKline Share Option Plan - Ordinary Shares
|
|
Period of return:
|
From:
|
1 November 2018
|
To:
|
30 April 2019
|
|
Balance of unallotted securities under scheme(s) from previous
return:
|
2,223,352
|
|
Plus:
The amount by
which the block scheme(s) has been increased since the date of the
last return (if any increase has been applied
for):
|
0
|
|
Less:
Number
of
securities
issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
958,344
|
|
Equals:
Balance
under scheme(s) not yet issued/allotted at end of
period:
|
1,265,008
|
|
|
|
Name of contact:
|
Victoria Whyte
|
|
Telephone number of contact:
|
020 8047 5000
|
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must
be typed or printed electronically and provided to
an
ris
.
Date:
13 May
2019
|
Name of
applicant
:
|
GlaxoSmithKline plc
|
|
Name of scheme:
|
GlaxoSmithKline Share Option Plan - ADS
|
|
Period of return:
|
From:
|
1 November 2018
|
To:
|
30 April 2019
|
|
Balance of unallotted securities under scheme(s) from previous
return:
|
7,336,096
|
|
Plus:
The amount by
which the block scheme(s) has been increased since the date of the
last return (if any increase has been applied
for):
|
0
|
|
Less:
Number
of
securities
issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
1,424,800
|
|
Equals:
Balance
under scheme(s) not yet issued/allotted at end of
period:
|
5,911,296
|
|
|
|
Name of contact:
|
Victoria Whyte
|
|
Telephone number of contact:
|
020 8047 5000
|
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must
be typed or printed electronically and provided to
an
ris
.
Date:
13 May
2019
|
Name of
applicant
:
|
GlaxoSmithKline plc
|
|
Name of scheme:
|
GlaxoSmithKline plc Share Save Plan 2012
|
|
Period of return:
|
From:
|
1 November 2018
|
To:
|
30 April 2019
|
|
Balance of unallotted securities under scheme(s) from previous
return:
|
5,672,623
|
|
Plus:
The amount by
which the block scheme(s) has been increased since the date of the
last return (if any increase has been applied
for):
|
0
|
|
Less:
Number
of
securities
issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
3,345,727
|
|
Equals:
Balance
under scheme(s) not yet issued/allotted at end of
period:
|
2,326,896
|
|
|
|
Name of contact:
|
Victoria Whyte
|
|
Telephone number
of
contact:
|
020 8047 5000
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
13, 2019
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
